Affiliation:
1. Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital: Saglik Bakanligi Istanbul Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EA Hastanesi
Abstract
Abstract
Background: In our patient, who was diagnosed with metastatic colorectal cancer, who received a chemotherapy regimen containing oxaliplatin; We present successful desensitization after omaizumab in addition to our premedication scheme
Case presentation: 39 years,F. She underwent hemicolectomy and liver metastasectomy with the diagnosis of metastatic colon adenocarcinoma. Chemotherapy regimen consisting of 5 florauracil + Bevacizumab + Oxaliplatin was started. After completing infusions of 5 florauracil while she was receiving her fourth chemotherapy; In the 20th minute of the oxaliplatin infusion, redness and itching began in the palms. While her whole body was red,she had abdominal pain, low back pain, she had no other systemic findings. His blood pressure was 90/60 mmHg. With premedication, oxaliplatin was given in 12 dilutions of 3 bottles with the M.Castel scheme. In the 11th step, at the 5th minute, redness and itching developed on the face and palms. She stated that she had chest and abdominal pain with hypotansıon. After the current condition was treated, 92 mg of oxaliplatin could be given while the target dose was 120 mg . , a single dose of omalizumab 150 mg sc was administered the day before. Standard premedication was also given. The infusion was prepared as 4 bottles of 16 steps. The first three bottles were completed without any problems. Based on her previous reaction, additional premedication was given after Step 14.The desensitization scheme was successfully completed by taking the target dose of 120 mg in total.
Conclusıons: We were able to reach the target oxaliplatin dose successfully after our omalizumab administration an additional day before. Although more studies are needed on this subject, we think that omalizumab can be added to the standard premedication schemes of clinics in high-risk patients.
Publisher
Research Square Platform LLC